3'-UTR poly(T/U) tract deletions and altered expression of EWSR1 are a hallmark of mismatch repair-deficient cancers.

Cancer Res

Authors' Affiliations: Biozentrum, University of Basel; Research Group Human Genetics, Dept of Biomedicine, University of Basel, and Division of Medical Genetics, University Hospital Basel; Institute for Surgical Research and Hospital Management and Department of Biomedicine, University of Basel; Institute of Pathology, University Hospital of Basel, Basel; Pathologie Laenggasse Bern, Bern; Institute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland; Department of Medical Genetics, Haartman Institute, University of Helsinki, Helsinki, Finland; and Paterson Institute for Cancer Research, University of Manchester, Manchester, United Kingdom.

Published: January 2014

The genome-wide accumulation of DNA replication errors known as microsatellite instability (MSI) is the hallmark lesion of DNA mismatch repair (MMR)-deficient cancers. Although testing for MSI is widely used to guide clinical management, the contribution of MSI at distinct genic loci to the phenotype remains largely unexplored. Here, we report that a mononucleotide (T/U)16 tract located in the 3' untranslated region (3'-UTR) of the Ewing sarcoma breakpoint region 1 (EWSR1) gene is a novel MSI target locus that shows perfect sensitivity and specificity in detecting mismatch repair-deficient cancers in two independent populations. We further found a striking relocalization of the EWSR1 protein from nucleus to cytoplasm in MMR-deficient cancers and that the nonprotein-coding MSI target locus itself has a modulatory effect on EWSR1 gene expression through alternative 3' end processing of the EWSR1 gene. Our results point to a MSI target gene-specific effect in MMR-deficient cancers.

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-2100DOI Listing

Publication Analysis

Top Keywords

mmr-deficient cancers
12
ewsr1 gene
12
msi target
12
mismatch repair-deficient
8
repair-deficient cancers
8
target locus
8
msi
6
ewsr1
5
cancers
5
3'-utr polyt/u
4

Similar Publications

The expression of BHLHE22 in endometrial carcinoma: Associations with mismatch repair protein expression status, tumor-infiltrating immune cells, programmed death-ligand 1 and clinical outcomes.

Taiwan J Obstet Gynecol

January 2025

Department of Pathology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, 23561, Taiwan; Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, 11031, Taiwan. Electronic address:

Objective: Endometrial cancer (EC) shows substantial heterogeneity in their immune microenvironment. BHLHE22 is consistently hypermethylated in EC and high expression of BHLHE22 is likely to be immunosuppressive in the tumor microenvironment. Herein, we evaluated expression of BHLHE22, programmed cell death ligand-1 (PD-L1), CD8, CD68 and mismatch repair proteins in EC.

View Article and Find Full Text PDF

DNA mismatch repair (MMR) gene mosaicism is rare in people with MMR-deficient cancers.

Gastroenterology

January 2025

Colorectal Oncogenomics Group, Department of Clinical Pathology, Victorian Comprehensive Cancer Centre, The University of Melbourne, Melbourne, VIC, 3010, Australia; University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Melbourne, VIC, 3010, Australia; Genomic Medicine and Family Cancer Clinic, Royal Melbourne Hospital, Parkville, VIC, 3000, Australia.

View Article and Find Full Text PDF

Mutational signature analysis predicts bacterial hypermutation and multidrug resistance.

Nat Commun

January 2025

Department of Biochemistry and Molecular Biology, School of Medicine, Tulane University, New Orleans, LA, USA.

Article Synopsis
  • Pseudomonas aeruginosa, when losing DNA mismatch repair (MMR), becomes a hypermutator, leading to high rates of multidrug resistance (MDR), especially after exposure to antibiotics.
  • Hypermutated MMR-deficient P. aeruginosa has a specific mutational signature and quickly develops MDR through shared resistance mechanisms across different drug classes.
  • Analyzing mutational signatures of P. aeruginosa in patients shows many MMR-deficient strains are already MDR or likely to become resistant, indicating that this analysis could be a valuable diagnostic tool for predicting and managing MDR in clinical settings.
View Article and Find Full Text PDF

Mismatch repair, p53, and L1 cell adhesion molecule status influence the response to chemotherapy in advanced and recurrent endometrial cancer.

BMC Cancer

December 2024

Department of Obstetrics and Gynecology, Institution of Women's Medical Life Science, Yonsei University College of Medicine, 50-1 Yonsei-Ro, Seodaemun-Gu, Seoul, 03722, Korea.

Objective: This study aimed to identify the recurrence and survival rates according to the mismatch repair (MMR), p53, and L1 cell adhesion molecule (L1CAM) status in patients with advanced and recurrent endometrial cancer (EC) receiving systemic chemotherapy.

Methods: This single-center retrospective cohort study included chemotherapy-naïve patients with advanced-stage (III/IV) or recurrent EC between January 2015 and June 2022 (n = 156), who were administered chemotherapy as adjuvant therapy or first-line palliative treatment. MMR and p53 status were assessed, and L1CAM was tested using immunohistochemistry in the p53-wild and MMR-proficient (p53wt/pMMR) group.

View Article and Find Full Text PDF

The molecular classification of endometrial cancer developed by The Cancer Genome Atlas project (TCGA, 2013) is currently actively used in gynecological oncology. According to it, endometrial carcinoma is divided into four molecular subtypes: -mutated, MMR deficient (dMMR), -aberrant and unspecified. Endometrial cancer samples belonging to the dMMR and -mutant types are characterized by specific genetic profiles reflecting the hyper- and ultramutant phenotypes of the tumor.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!